| 19/114 |
Anti-Human Neutrophil Antibody 3a WHO Reference Reagent |
| 18/248 |
Von Willebrand Factor Concentrate (WHO 3rd International Standard) |
| 21/266 |
1st International Standard 2022 Anti-β2GPI IgG 200 IU/Vial |
|
Product Code
| Infectious diseases |
|---|
| 18/180 |
2nd International Standard for Diphtheria Antitoxin Equine |
| Dim9 |
Diphtheria toxoid monoclonal antibody, clone Dim9 |
| DT05 |
Diphtheria toxoid monoclonal antibody, clone DT05 |
|
Product Code
| Emerging viruses |
|---|
| 21/112 |
First WHO International Standard for LASV RNA |
| 22/108 |
Reference Panel for Lassa virus RNA |
| 21/110 |
Working Reagent for Lassa virus RNA |
| 22/218 |
Working Reagent for anti-monkeypox virus antibodies |
|
Product Code
| Influenza |
|---|
| 22/222 |
Influenza Antigen A/Sydney/175/2022 (IVR-235) (H1N1) |
| 22/220 |
Influenza Antigen A/Sydney/5/2021 (SAN-013) (H1N1) |
| 22/100 |
Influenza Antigen A/Victoria/2570/2019 (IVR-215) (H1N1) |
| |
Influenza Antiserum |
| 22/224 |
Influenza anti-A/Sydney/5/2021-like (H1N1) HA serum |
| |
Influenza Virus |
| 22/146 |
Influenza Virus Infectious A/Brisbane/02/2018 (H1N1) |
| 22/178 |
Influenza Virus Infectious A/Darwin/22/2021 (H3N2) NIB -130 |
| 22/144 |
Influenza Virus Infectious A/Darwin/22/2021 (H3N2) SAN-014 |
| 22/180 |
Influenza Virus Infectious A/Guizhou/Liuzhite/326/2022 (H3N2) CNIC-2206 |
| 22/138 |
Influenza Virus Infectious A/Indiana/02/2020 (H1N1) |
| 22/172 |
Influenza Virus Infectious A/Lyon/820/2021 (H1N1) NIB-132 |
| 22/140 |
Influenza Virus Infectious A/Netherlands 00007/2021 (H3N2) SAN-012 |
| 22/158 |
Influenza Virus Infectious A/Netherlands/00007/2021 (H3N2) NYMC X-377 |
| 22/136 |
Influenza Virus Infectious A/North Carolina/01/2021 (H1N1) X-375 |
| 22/156 |
Influenza Virus Infectious A/Norway/16606/2021 (H3N2) NYMC X373A |
| 22/200 |
Influenza Virus Infectious A/Sydney/5/2021 (H1N1) |
| 22/142 |
Influenza Virus Infectious A/Sydney/5/2021 (H1N1) SAN-013 |
| 22/174 |
Influenza Virus Infectious A/Victoria/2570/2019 (H1N1) NYMC X-379 |
| 22/204 |
Influenza Virus Infectious B/Austria/1359417/2021 (B-Victoria lineage) BVR-26 |
| 22/154 |
Influenza Virus Infectious B/Connecticut/01/2021 (B-Victoria Lineage) |
| 21/388 |
Influenza Virus Infectious B/Guangdong-Zhenjiang/1516/2021 (B-Victoria Lineage) |
| 22/134 |
Influenza Virus Infectious BX-107A (B-Victoria Lineage) |
| 22/214 |
Influenza Virus Infectious CBER-48A (A/Sydney/5/2021) (H1N1) |
| 22/234 |
Influenza Virus Infectious IVR-235 (A/Sydney/175/2022) (H1N1) |
| 22/118 |
Influenza Virus Infectious NIB-129 (H3N2) |
| 22/268 |
Influenza Virus Infectious SAN-015 (A/Lyon/820/2021) (H1N1) |
| 21/382 |
Influenza Virus Infectious X-367A (H3N2) |
| 21/384 |
Influenza Virus Infectious X-369A (H3N2) |
|
Product Code
| Microbiome |
|---|
| 22/212 |
NIBSC Reference Reagent for DNA extractions of gut microbiome samples (WC-Gut-RR) |
| 20/302 |
WHO International Reference Reagent for GUT Microbiome analysis by NGS (Gut-Mix RR) |
| 20/304 |
WHO Reference Reagent for GUT Microbiome analysis by NGS (DNA-Gut-HiLo) |
|
Product Code
| Monoclonal antibodies |
|---|
| 22/242 |
Anti-pneumococcal serotype 11A monoclonal antibody |
| 22/256 |
Anti-pneumococcal serotype 15A/B monoclonal antibody |
| 22/244 |
Anti-pneumococcal serotype 15B monoclonal antibody |
| 22/258 |
Anti-pneumococcal serotype 16F monoclonal antibody |
| 22/246 |
Anti-pneumococcal serotype 17F monoclonal antibody |
| 22/260 |
Anti-pneumococcal serotype 19F monoclonal antibody |
| 22/236 |
Anti-pneumococcal serotype 2 monoclonal antibody |
| 22/248 |
Anti-pneumococcal serotype 20 monoclonal antibody |
| 22/262 |
Anti-pneumococcal serotype 23F monoclonal antibody |
| 22/264 |
Anti-pneumococcal serotype 24F monoclonal antibody |
| 22/250 |
Anti-pneumococcal serotype 33F monoclonal antibody |
| 22/266 |
Anti-pneumococcal serotype 35B monoclonal antibody |
| 22/238 |
Anti-pneumococcal serotype 4 monoclonal antibody |
| 22/240 |
Anti-pneumococcal serotype 6B monoclonal antibody |
| 22/254 |
Anti-pneumococcal serotype 6C monoclonal antibody |
| 32-1 |
Filamentous Haemagglutinin monoclonal antibody, clone 32-1 |
| FHADETOX/6 |
Filamentous Haemagglutinin monoclonal antibody, clone FHADETOX/6 |
| 1-7 |
Fimbrae monoclonal antibody, clone 1-7 |
| G10F8C3 |
Fimbrae monoclonal antibody, clone G10F8C3 |
| 3-5 |
Pertactin Monoclonal antibody, Clone 3-5 |
| 69K/16 |
Pertactin monoclonal antibody, clone 69K/16 |
| 629 e1 |
Pertussis toxoid monoclonal antibody, clone 629E1 |
| PS21C2.2.1 |
Pertussis toxoid monoclonal antibody, clone PS21C2.2.1 |
| 21/230 |
1st WHO Reference Reagent Tetanus Antitoxin Equine for use in Flocculation Test |
| 8E1-1H1.2.1 |
Tetanus toxoid monoclonal antibody, clone 8E1-1H1.2.1 |
| TT010 |
Tetanus toxoid monoclonal antibody, clone TT010 |
|
Product Code
| COVID-19 |
|---|
| 22/B896-01 |
Anti-SARS-CoV-2 Verification Panel for Serology Assays |
| 101062 |
HEK293T-ACE2-30F-PLP2 |
| 101037 |
Inactivated (acetic acid + heat) SARS-Cov-2 Gamma (P.1 lineage) |
| 101047 |
Inactivated (Acetic Acid + Heat)SARS-CoV-2 Omicron (BA.1 sublineage) |
| 21/338 |
1st International Standard for antibodies to SARS-CoV-2 variants of concern |
| 20/270 |
SARS-CoV-2 Ag QC |
| 20/270-002 |
SARS-CoV-2 Ag QC |
| 21/368 |
SARS-Cov-2 Antigen 1st WHO International Standard |
| 101055 |
SARS-CoV-2 Omicron (BA.2) |
| 101054 |
SARS-CoV-2 Omicron BA.1.1 sublineage lot 28032022 |
|
Product Code
| Serology diagnostics |
|---|
| 03/104-022 |
HTLV-1 (antibody) Monitor Sample |
| 20/168-002 |
Monitor Sample for Anti HTLV-II |
| 20/168-003 |
Monitor Sample for Anti HTLV-II |
| 21/B889-01 |
QCRHCVQC1-Anti-HCV Quality Control Serum: Sample1 |
| 21/B882-01 |
QCRHSV1QC1-Anti-HSV1 Quality Control Serum: Sample1 |
| 22/B891-01 |
QCRTOXOIgMQC1 IgM Anti-Toxoplasma QC1 |